Toll-like receptors and dermatology

International Journal of Dermatology

Volumn 48, Issue 6, 2009, Pages 558-570

  Petry, Vanessa ^a   Gaspari, Anthony A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGATOLIMOD; ALPHA INTERFERON; BROPIRIMINE; CELL MEMBRANE PROTEIN; CHLOROQUINE; HEAT SHOCK PROTEIN; IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; LOXORIBINE; PROTEIN UNC 93B; RESIQUIMOD; RETINOIC ACID; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 8; UNCLASSIFIED DRUG;

ACNE VULGARIS; ATOPIC DERMATITIS; BACTERIAL INFECTION; BASAL CELL CARCINOMA; DRUG MECHANISM; HERPES SIMPLEX; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INNATE IMMUNITY; LEPROSY; LYME DISEASE; MELANOMA; NONHUMAN; PRECANCER; PRIMARY TUMOR; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSORIASIS; REVIEW; SKIN CANCER; SKIN DISEASE; SKIN METASTASIS; SKIN TUMOR; SYPHILIS; SYSTEMIC LUPUS ERYTHEMATOSUS; VERRUCA VULGARIS; VIRUS ENCEPHALITIS;

DERMATOLOGY; HUMANS; SIGNAL TRANSDUCTION; SKIN DISEASES; TOLL-LIKE RECEPTORS;

EID: 66849099662     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2009.04111.x     Document Type: Review

References (129)

1. Belvin MP, Anderson KV. A conserved signaling pathway: The Drosophila toll-dorsal pathway. Annu Rev Cell Biol 1996; 12: 393-416.
2. Kaisho T, Akira S. Toll-like receptor function and signaling. J Allergy Clin Immunol 2006; 117: 979-987.
3. Anderson KV, Nusslein-Volhard C. Information for the dorsal-ventral pattern of the Drosophila embryo is stored as maternal mRNA. Nature 1984; 311: 223-227.
4. Cohen B. Nobel committee rewards pioneers of development studies in fruitflies. Nature 1995; 377: 465.
5. Hashimoto C, Hudson K, Anderson K. The toll gene in Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell 1988; 52: 169-179.
6. Lemaitre B, Nicholas E, Michaut L, et al. The dorso ventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996; 86: 973-983.
7. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptative immunity. Nature 1997; 338: 394-397.
8. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-376.
9. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
10. Beutler B, Jiang Z, Georgel P, et al. Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu Rev Immunol 2006; 24: 353-389.
11. Kang SSW, Kauls LS, Gaspari AA. Toll-like receptors: Applications to dermatologic disease. J Am Acad Dermatol 2006; 54: 951-983.
12. Du X, Poltorak A, Wei Y, Beutler B. Three novel mammalian toll-like receptors: Gene structure, expression, and evolution. Eur Cytokine Netw 2000; 11: 362-371.
13. 9. Eur Cytokine Netw 2000; 11: 372-378.
14. Mish EA, Hawn TR. Toll-like receptor polymorphisms and susceptibility to human disease. Clin Sci 2008; 114: 347-360.
15. Mempel M, Kalai BN, Ollet M, et al. Toll-like receptors in dermatology. Dermatol Clin 2007; 25: 531-540.
16. Kollisch G, Kalali BN, Voelcker V, et al. Various members of the Toll-like receptor family contribute to the innate immune response of human epidermal keratinocytes. Immunology 2005; 114: 531-541.
17. Mempel M, Voelcker V, Kollisch G, et al. Toll-like receptor expression in human keratinocytes: Nuclear factor kappaB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent. J Invest Dermatol 2003; 121: 1389-1396.
18. Miller LS, Sorensen OE, Liu TP, et al. TGF-alpha regulates TLR expression and function on epidermal keratinocytes. J Immunol 2005; 174: 6137-6143.
19. Pivarcsi A, Bodai L, Rethi B, et al. Expression and function of Toll-like receptors 2 and 4 in human keratinocytes. Int Immunol 2003; 15: 721-730.
20. Lebre MC, Antons JC, Kalinski P, et al. Double-stranded RNA-exposed human keratinocytes promote Th1 responses by inducing a Type 1 polarized phenotype in dendritic cells: Role of keratinocyte-derived-tumor necrosis factor alpha, type I interferons and interleukin-18. J Invest Dermatol 2003; 120: 990-997.
21. Renn CN, Sanchez DJ, Ochoa MT, et al. TLR activation of Langerhans cell-like dendritic cells triggers an antiviral immune response. J Immunol 2006; 177: 298-305.
22. Ahn JH, Park TJ, Jin SH, et al. Human melanocytes express functional Toll-like receptor 4. Exp Dermatol 2008; 17: 412-417.
23. Dearman RJ, Cumberbatch M, Maxwell G, et al. Toll-like receptor ligand activation of murine bone marrow-derived dendritic cells. Immunology 2009; in press.
24. 4 by TLR ligand-stimulated nasal polyp fibroblasts. Acta Otolaryngol 2007; 127: 1304-1309.
25. Harper JC, Thiboutot DM. Pathogenesis of acne: Research advances. Adv Dermatol 2003; 19: 1-10.
26. Vowels BR, Yang S, Leyden JJ. Introduction of proinflammatory cytokines by a soluble factor of Propionibacteruim acnes: Implications for chronic inflammatory acne. Infect Immun 1995; 63: 3158-3165.
27. Kim J, Ochoa MT, Krutzik SR, et al. Activation of Toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 2002; 169: 1535-1541.
28. Heymann WR. Toll-like receptors in acne vulgaris. J Am Acad Dermatol 2006; 55: 691-692.
29. Lin PT, Krutzik SR, Kim J, et al. Cutting edge: All-trans retinoic acid down-regulates TLR2 expression and function. J Immunol 2005; 174: 2467-2470.
30. Krutzik SR, Modlin RL. The role of Toll-like receptors in combating mycobacteria. Semin Immunol 2004; 16: 35-41.
31. Krutzik SR, Ochoa MT, Sieling PA, et al. Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nat Med 2003; 9: 525-532.
32. Misch EA, Macdonald M, Ranjit C, et al. Human TLR1 deficiency is associated with impaired mycobacterial signaling and protection from leprosy reversal reaction. Plos Negl Trop Dis 2008; 2: E231.
33. Bochud PY, Hawn TR, Siddiqui MR. Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. J Infect Dis 2008; 197: 253-261.
34. Underhill DM, Smith KD, Aderem A. Toll-like receptor 2 mediates mycobacteria-induced proinflammatory signaling in macrophages. Proc Natl Acad Sci 1999; 96: 14, 459-14, 463.
35. Kan T, Chae G. Detection of Toll-like receptor 2 (TLR2) mutation in lepromatous leprosy patients. FEMS Immunol Med Microbiol 2001; 31: 53-58.
36. Oliveira RB, Ochoa MT, Sieling PA, et al. Expression of Toll-like receptor 2 on human Schwann cells: A mechanism of nerve damage in leprosy. Infect Immun 2003; 71: 1427-1433.
37. Tramont EC. Treponema pallidum (syphilis). In: Mandell GL, Bennet JE, Colin R, eds. Principles and Practice of Infectious Diseases, 5th edn. New York: Churchill Livingstone, 2000: 2474.
38. Van Voorhis WC, Barret LK, Koelle DM, et al. Primary and secondary syphilis lesions contain mRNA for TH1 cytokines. J Infect Dis 1996; 173: 491-495.
39. Hertz CJ, Kiertscher SM, Godowski PJ, et al. Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2. J Immunol 2001; 166: 2444-2450.
40. Sieling PA, Chung W, Duong BT, et al. Toll-like receptor 2 ligands as adjuvants for human Th1 responses. J Immunol 2003; 170: 194-200.
41. Moors MA, Li L, Mizel SB. Activation of interleukin-1 receptor-associated kinase by gram-negative flagellin. Infect Immun 2001; 69: 4424-4429.
42. 4 complexes. J Immunol 2003; 170: 6217-6223.
43. Girschick HJ, Huppertz HI, Russmann H, et al. Intracellular persistence of Borrelia burgdorferi in human synovial cells. Rheumatol Int 1996; 16: 25-132.
44. Wooten RM, Modur VR, McIntyre TM, et al. Borrelia burgdorferi outer membrane protein A induces nuclear translocation of nuclear factor-kappa B and inflammatory activation in human endothelial cells. J Immunol 1996; 157: 4584-4590.
45. Ma Y, Seiler KP, Tai KF, et al. Outer surface lipoproteins of Borrelia burgdorferi stimulate nitric oxide production by the cytokine-inducible pathway. Infect Immun 1994; 62: 3663-3671.
46. Norgard MV, Arndt LL, Akins DR, et al. Activation of human monocytic cells by Treponema pallidum and Borrelia burgdorferi lipoproteins and synthetic lipopeptides proceeds via a pathway distinct from that of lipopolysaccharide but involves the transcriptional activator NF-kappa B. Infect Immun 1996; 64: 3845-3852.
47. Morrison TB, Weis JH, Weis JJ. Borrelia burgdorferi outer surface protein A (OspA) activates and primes human neutrophils. J Immunol 1997; 158: 4838-4845.
48. Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002; 168: 554-561.
49. Flo TH, Halaas O, Torp S, et al. Differential expression of Toll-like receptor 2 in human cells. J Leukoc Biol 2001; 69: 474-481.
50. 3H/HeJ mice. FEMS Microbiol Lett 2004; 231: 219-225.
51. Wang G, Ojaimi C, Iyer R, et al. Impact of genotypic variation of Borrelia burgdorferi sensu stricto on kinetics of dissemination and severity of disease in C3H/HeJ mice. Infect Immun 2001; 69: 4303-4312.
52. Singh SK, Girschick HJ. Toll-like receptors in Borrelia burgdorferi -induced inflammation. Clin Microbiol Infect 2006; 12: 705-717.
53. Alexopoulou L, Thomas V, Schnare M, et al. Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nat Med 2002; 8: 878-884.
54. Schröder NW, Eckert J, Stübs G, et al. Immune responses induced by spirochetal outer membrane lipoproteins and glycolipids. Immunobiology 2008; 213: 329-340.
55. Kinjo Y, Tupin E, Wu D, et al. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat Immunol 2006; 7: 978-986.
56. Leung DY. Atopic dermatitis: New insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000; 105: 860-876.
57. Breuer K, Kapp A, Werfel T. Bacterial infections and atopic dermatitis. Allergy 2001; 56: 1034-1041.
58. Matsui K, Nishikawa A, Suto H, et al. Comparative study of Staphylococcus aureus isolated from lesional and non-lesional skin of atopic dermatitis patients. Microbiol Immunol 2000; 44: 945-947.
59. Breuer K, Wittmann M, Bösche B, et al. Severe atopic dermatitis is associated with sensitization to staphylococcal enterotoxin B (SEB). Allergy 2000; 55: 551-555.
60. Leung DY, Harbeck R, Bina P, et al. Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. J Clin Invest 1993; 92: 1374-1380.
61. Skov L, Olsen JV, Giorno L, et al. Application of Staphylococcus enterotoxin B on normal and atopic skin induces up-regulation of T-cells by a superantigen-mediated mechanism,. J Allergy Clin Immunol 2000; 105: 820-826.
62. Kotzin BL, Leung DYM, Kappler J, et al. Superantigens and their potential role in human disease. Adv Immunol 1993; 54: 99-166.
63. Harder J, Bartels J, Christophers E, et al. A peptide antibiotic from human skin. Nature 1997; 387: 861.
64. O'Neill DA, Porter EM, Elewaut D, et al. Expression and regulation of the human β-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol 1999; 163: 6718-6724.
65. Birchler T, Seibl R, Büchner K, et al. Human Toll-like receptor 2 mediates induction of the antimicrobial peptide human beta-defensin 2 in response to bacterial lipoprotein. Eur J Immunol 2001; 31: 3131-3137.
66. 753Q polymorphism defines a subgroup of patients with atopic dermatitis having severe phenotype. J Allergy Clin Immunol 2004; 113: 565-567.
67. Niebuhr M, Langnickel J, Draing C et al. Dysregulation of toll-like receptor-2 (TLR-2)-induced effects in monocytes from patients with atopic dermatitis: Impact of the TLR-2 R753Q polymorphism. Allergy 2008; 63: 728-734.
68. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003; 56: 481-490.
69. D'Cruz DP, Khamashta MA, Hughes GRV. Systemic lupus erythematosus. Lancet 2007; 369: 587-596.
70. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006; 6: 823-835.
71. Krieg AM, Vollmer J. Toll-like receptors 7, 8 and 9: Linking innate immunity to autoimmunity. Immunol Rev 2007; 220: 251-269.
72. Christensen SR, Shlomchik MJ. Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors. Semin Immunol 2007; 19: 11-23.
73. Means TK, Luster AD. Toll-like receptor activation in the pathogenesis of systemic lupus erythematosus. Ann N Y Acad Sci 2005; 1062: 242-251.
74. Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1990; 115: 178-183.
75. Ronnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med 1990; 227: 207-210.
76. Ehrestein MR, McSweeney E, Sware M, et al. Appearance of anti-DNA antibodies in patients treated with interferon-alpha. Arthritis Rheum 1993; 36: 279-280.
77. Komatsuda A, Wakui H, Iwamoto M, et al. Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol 2008; 152: 482-487.
78. Kwok SK, Lee JY, Park SH, et al. Dysfunctional interferon-alpha production by peripheral plasmacytoid dendritic cells upon Toll-like receptor-9 stimulation in patients with systemic lupus erythematosus. Arthritis Res Ther 2008; 10: R29.
79. 937 cells and lupus IgG is a potent IFN-alpha inducer. J Immunol 2000; 165: 3519-3526.
80. Lovgren T, Eloranta ML, Bave U, et al. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 2004; 50: 1861-1872.
81. Ghosh TK, Mickelson DJ, Fink J, et al. Toll-like receptor (TLR) 2-9 agonists-induced cytokines and chemokines. I. Comparison with T cell receptor-induced responses. Cell Immunol 2006; 243: 48-57.
82. 7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides. Eur J Immunol 2006; 36: 1815-1826.
83. Gottenberg JE, Cagnard N, Lucchesi C. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc Natl Acad Sci USA 2006; 103: 2770-2775.
84. Yasuda H, Leelahavanichkul A, Tsunoda S, et al. Chloroquine and inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury. Am J Physiol Renal Physiol 2008; 294: F1050-F1058.
85. 7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets 2007; 6: 223-235.
86. Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 2007; 20: 160-174.
87. Noah PW. The role of microorganisms in psoriasis. Semin Dermatol 1990; 9: 269.
88. Baker BS, Ovigne JM, Powles AV, et al. Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: Modulation of TLR expression in chronic psoriasis. Br J Dermatol 2003; 148: 670-679.
89. Zahng L, Pelech SL, Maurand D, et al. Bacterial heat shock protein-60 increases epithelial cell proliferation through the ERK1/2 MAP kinase. Exp Cell Res 2001; 266: 11.
90. Young RA. Stress proteins and immunology. Annu Rev Immunol 1990; 8: 401.
91. Rambukkana A, Das PK, Wirkamp L, et al. Antibodies to mycobacterial 65-kDa heat shock protein and other immunodominant antigens in patients with psoriasis. J Invest Dermatol 1993; 100: 87.
92. 4 complex. J Immunol 2000; 164: 558.
93. 40MyD88 pathway. J Immunol 2005; 175: 3594.
94. Sadia P, Kafrawy AH, Miles DA, et al. Heat shock protein induced TCRγδ gene rearrangements in patients with oral cancer. Oral Oncol 2005; 41: 175.
95. Seung NR, Park EJ, Kim CW, et al. Comparison of expression of heat-shock protein 60, Toll-like receptors 2 and 4, and T-cell receptor δ in plaque and guttate psoriasis. J Cutan Pathol 2007; 34: 903-911.
96. Zanin-Zhorov A, Nussbaum G, Franitza S, et al. T cells respond to heat shock protein 60 via TLR2: Activation of adhesion and inhibition of chemokine receptors. FASEB J 2003; 127: 78.
97. 4. J Biol Chem 2001; 276: 10, 229-10, 233.
98. Ting KM, Rothaupt D, McCormick TS et al. Overexpression of the oncofetal Fn variant containing the EDA splice-in segment in the dermal-epidermal junction of psoriatic uninvolved skin. J Invest Dermatol 2000; 114: 706-711.
99. Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 2006; 54 (Suppl. 2): S67-S80.
100. 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 2004; 104: 1490-1495.
101. 7 mediated recognition of single-stranded RNA. Science 2004; 303: 1529-1531.
102. Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007; 449: 564-569.
103. Rivas JM, Ullrich SE. Systemic suppression of delayed-type hypersensitivity by supernatants from UV-irradiated keratinocytes. An essential role for keratinocyte-derived IL-10. J Immunol 1992; 76: 254-271.
104. Yoshikawa T, Kurimoto I, Streilein JW. Tumor necrosis factor-alpha mediates ultraviolet light B-enhanced expression of contact hypersensitivity. Immunology 1992; 76: 254-271.
105. Vabulas RM, Wagner H, Schild H. Heat shock proteins as ligands of toll-like receptors. Curr Top Microbiol Immunol 2002; 270: 169-184.
106. Yusuf N, Nasti TH, Long JA, et al. Protective role of Toll-like receptor 4 during the initiation stage of cutaneous chemical carcinogenesis. Cancer Res 2008; 68: 615-622.
107. 7 and TLR8 as targets in cancer therapy. Oncogene 2008; 27: 190-199.
108. 4 deficiency Science 2003; 299: 2076-2079.
109. 4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J Exp Med 2003; 198: 521-531.
110. 4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med 2007; 204: 2407-2422.
111. Ahmad-Nejad P, Häcker H, Rutz R, et al. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 2002; 32: 1958-1968.
112. 93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes. Nature 2008; 452: 234-238.
113. Schillinger JA, Xu F, Sternberg MR, et al. National seroprevalence and trends in herpes simplex virus type 1 in the United States, 1976-94. Sex Transm Dis 2004; 31: 753-760.
114. 93B deficiency. Science 2006; 314: 308-312.
115. 3 deficiency in patients with herpes simplex encephalitis. Science 2007; 317: 1522-1527.
116. 7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3: 196-200.
117. 27609. J Interferon Cytokine Res 1995; 15: 537-545.
118. Suzuki H, Wang B, Shivhi GM, et al. Imiquimod, a topical immune response modifier induces migration of Langerhans cells. J Invest Dermatol 2000; 114: 135-141.
119. Kodner CM, Nasraty S. Management of genital warts. Am Fam Physician 2004; 70: 2335-2342.
120. Schon MP, Schon M. Immune modulation and apoptosis induction: Two sides of the antitumoral activity of imiquimod. Apoptosis 2004; 9: 291-298.
121. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303: 1526-1529.
122. Jurk M, Heil F, Vollmer J, et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 2002; 3: 499.
123. Schön MP, Schön M, Klotz KN. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol 2006; 126: 1338-1347.
124. Thatcher TH, Luzina I, Fishelevich R, et al. Topical imiquimod treatment prevents UV-light induced loss of contact hypersensitivity and immune tolerance. J Invest Dermatol 2006; 126: 821-831.
125. Heil F, Ahmad-Nejad P, Hemmi H, et al. The Toll-like receptor 7 (TLR7) specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol 2003; 3: 2987-2997.
126. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003; 85: 85-95.
127. Goodman MG. A new approach to vaccine adjuvants. Immunopotentiation by intracellular T-helper-like signals transmitted by loxoribine. Pharm Biotechnol 1995;6: 581-609.
128. Agarwala SS, Kirkwood JM, Bryant J. Phase 1, randomized, double-blind trial of 7-allyl-8-oxoguanosine (loxoribine) in advanced cancer. Cytokines Cell Mol Ther 2000;6: 171-176.
129. Hofmann MA, Kors C, Audring H. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother 2008;31: 520-527.